- Home
- Healthcare professionals
- ACE Technology Guidances
- Drug Guidance
- Endothelin receptor antagonists for treating pulmonary arterial hypertension
Drug guidance
Endothelin receptor antagonists for treating pulmonary arterial hypertension
Condition
Cardiovascular
2 September 2024
Published on 02 Sep 2019
Last Updated on 02 Sep 2024
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
Ambrisentan 5 mg and 10 mg tablets for treating adults with a confirmed diagnosis of WHO Functional Class II or III pulmonary arterial hypertension (PAH) who have one of the following PAH aetiologies:
Idiopathic PAH;
Heritable or familial PAH;
PAH associated with connective tissue disease;
Anorexigen-induced PAH; or
PAH associated with HIV infection.
Subsidy status
Ambrisentan 5 mg and 10 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.
MAF assistance does not apply to bosentan 62.5 mg and 125 mg tablets, and macitentan 10 mg tablet.